- Report
- May 2021
- 111 Pages
Global
From €3200EUR$3,560USD£2,848GBP
- Report
- March 2024
- 103 Pages
Global
From €3500EUR$3,893USD£3,115GBP
- Report
- September 2022
- 109 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Drug Pipelines
- September 2018
- 67 Pages
Global
From €3371EUR$3,500USD£2,899GBP
- Report
- July 2021
- 85 Pages
Global
From €3371EUR$3,500USD£2,899GBP
- Report
- April 2022
- 150 Pages
Global
From €3328EUR$3,456USD£2,862GBP
The Insomnia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Insomnia drugs are used to treat difficulty sleeping, and can be divided into two categories: sedative-hypnotics and non-sedative hypnotics. Sedative-hypnotics are drugs that act on the central nervous system to induce sleep, while non-sedative hypnotics are drugs that act on the brain to improve sleep quality without causing sedation. Commonly prescribed insomnia drugs include benzodiazepines, non-benzodiazepines, and melatonin receptor agonists.
Some companies in the Insomnia Drug market include Sanofi, Pfizer, Merck, GlaxoSmithKline, and Takeda. Show Less Read more
